Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
NEW YORK, Feb. 27, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Innocoll Holdings plc securities (NASDAQ:INNL) from November 3, 2016 through December 29, 2016, both dates inclusive (the “Class Period”) of the important March 27, 2017 lead plaintiff deadline in first-filed class action commenced by the Rosen Law Firm. The lawsuit seeks to recover damages for Innocoll investors under the federal securities laws.
To join the Innocoll class action, go to http://www.rosenlegal.com/cases-1019.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) as a result, Defendants’ statements about Innocoll’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1019.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
